Biovica receives USD 85,000 work order for Phase 1 oncology study testing

• Biovica received its first work order under a new Master Services Agreement, valued at about USD 85,000.
• Order covers DiviTum TKa testing in a first-in-human Phase 1 study of an oral next-generation CDK inhibitor.
• Testing will be run at Biovica’s Sweden laboratory for a study initially recruiting patients outside the US.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biovica International AB published the original content used to generate this news brief on September 22, 2026, and is solely responsible for the information contained therein.